Just before the 23andMe SPAC deal closed, the stock belonging to its merger ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets ...

Me’s debacle should be a major wake-up call, reminding policymakers and all of us of the risks of giving access to our ...

Today the market is a SPAC graveyard—with genetics testing startup 23andMe the latest casualty after declaring Chapter 11 bankruptcy late Sunday night. According to new data from the financial ...

23andme says it owns the aggregated genetic data of its customers, meaning it can sell it to the highest bidder ...

The direct-to-consumer DNA testing service 23andMe filed for bankruptcy earlier this month, putting millions of customers' ...

But since 23andMe is not a medical provider it does not have to abide by standard privacy policies that must be followed at a doctor's office. Such services are "not regulated well," said Ayday.

Genetic analysis company 23andMe (ME) announced this week it's declaring bankruptcy and pursuing a sale, leading many customers to pursue deleting their data from the company. 23andMe was founded ...

23andMe is going bankrupt — underscoring the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations. When companies opt ...

Just before the 23andMe SPAC deal closed ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets and have to redeem the ...

23andMe bankruptcy underscores the risk of investing in most SPACs. - MarketWatch photo illustration/iStockphoto 23andMe is going bankrupt — underscoring the great ...